An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Synchron Appoints Andy Rasdal to Board of Directors
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Synchron (SYN) announces the appointment of Andy Rasdal to its Board of Directors. Rasdal brings over 30 years of experience in developing and commercializing novel medical devices. He has led companies through FDA approval, IPO, and commercialization of innovative products, making him a valuable addition to Synchron's board. His career exposure to over 15 PMAs, particularly leading DexCom through FDA approval and eventual IPO, will be invaluable to Synchron. Rasdal's expertise will be crucial as Synchron moves towards pivotal study launch and eventual commercialization of its implantable brain-computer interface technology.
Positive
None.
Negative
None.
NEW YORK--(BUSINESS WIRE)--
Synchron, the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment, today announced the appointment of Andy Rasdal to its Board of Directors. Mr. Rasdal brings more than 30 years of experience of developing and commercializing novel medical devices.
Andy Rasdal, Board Member, Synchron (Photo: Business Wire)
As former CEO of DexCom, Inc. (NASDAQ:DXCM, Market Cap: $46 billion) he led the company through FDA approval, a successful IPO, and commercialization of its continuous glucose monitor (CGM) product for diabetes. He currently serves as executive chairman of Epitel, a company that developed the first wearable, wireless EEG system to detect seizure conditions. As founding CEO of Obalon Therapeutics, Inc., he led the company through FDA PMA approval, an IPO, and commercialization of a novel product for obesity.
“Andy joining the Board is a windfall for Synchron. He brings decades of operational experience in delivering first-to-market products through the FDA premarketing approval pathway,” said Tom Oxley, CEO & Founder, Synchron. “His career exposure to over 15 PMAs, in particular, leading DexCom through FDA approval and an eventual IPO, will be invaluable to Synchron.”
“I’m excited to join the Synchron Board of Directors. I believe in the company’s mission to become the first implantable brain computer interface to reach commercialization and help millions of people with paralysis reconnect with the world,” Rasdal said. “My experience is relevant to Synchron, especially as they move towards pivotal study launch and eventual commercialization. Synchron has a broad technology platform with the potential to become the market-leading implantable neurotechnology company.”
Before DexCom, Mr. Rasdal was President, Medtronic Vascular. Mr. Rasdal was the Vice President of Global Marketing at Arterial Vascular Engineering, Inc. (AVEI) which was purchased by Medtronic for $4.3 billion. Prior to AVE, Mr. Rasdal also held positions at EP Technologies (EPTI), which was acquired as a public company by Boston Scientific, and Advanced Cardiovascular Systems (ACS), which became the vascular division of Guidant and was ultimately acquired by Abbott.
Mr. Rasdal holds a Masters of Management from the Kellogg Graduate School of Management and a B.Sc. from San Jose State University.
About Synchron
Synchron is a neurotechnology company developing an endovascular brain-computer interface (BCI) designed to restore functionality in patients with severe paralysis. The clinical-stage company is developing a neuroprosthesis to restore motor signaling to control digital devices and restore autonomy for individuals with motor impairment. Synchron is headquartered in New York City. For more information, visit www.synchron.com. Follow us @synchroninc.
Who is appointed to Synchron's Board of Directors?
Andy Rasdal has been appointed to Synchron's Board of Directors.
What is Andy Rasdal's experience in the medical devices industry?
Rasdal brings over 30 years of experience in developing and commercializing novel medical devices.
What companies has Andy Rasdal led through FDA approval and commercialization of innovative products?
Andy Rasdal has led DexCom, Inc. through FDA approval, IPO, and commercialization of a continuous glucose monitor product for diabetes. He also led Obalon Therapeutics, Inc. through FDA PMA approval, an IPO, and commercialization of a novel product for obesity.
What is the significance of Andy Rasdal's appointment to Synchron's Board of Directors?
Rasdal's expertise in leading companies through FDA approval, IPO, and commercialization of innovative products will be invaluable to Synchron as it moves towards pivotal study launch and eventual commercialization of its implantable brain-computer interface technology.
